# Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)

> **NCT03252847** · PHASE1,PHASE2 · COMPLETED · sponsor: **MeiraGTx UK II Ltd** · enrollment: 49 (actual)

## Conditions studied

- X-Linked Retinitis Pigmentosa

## Interventions

- **GENETIC:** AAV5-RPGR

## Key facts

- **NCT ID:** NCT03252847
- **Lead sponsor:** MeiraGTx UK II Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-31
- **Primary completion:** 2021-11-18
- **Final completion:** 2021-11-18
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2025-01-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03252847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03252847, "Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03252847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*